Glossary of chemotherapy schedules

**AC-Paclitaxel in the NSABP B-28 trial:** doxorubicin (60 mg/m²) and cyclophosphamide (600 mg/m²) administered every 3 weeks for four cycles, followed by paclitaxel 225 mg/m² administered every 3 weeks for four cycles.

**AC-Paclitaxel in the CALGB 9344 trial:** doxorubicin (60, 75, or 90 mg/m²) and cyclophosphamide (600 mg/m²) administered every 3 weeks for four cycles, followed by paclitaxel 175 mg/m² administered every 3 weeks for four cycles.

**FAC in the BCIRG 001 trial:** 5-fluorouracil (500 mg/m²), doxorubicin (50 mg/m²), and cyclophosphamide (500 mg/m²) administered every 3 weeks for six cycles.

**TAC in the BCIRG 001 trial:** docetaxel (75 mg/m²), doxorubicin (50 mg/m²) and cyclophosphamide (500 mg/m²) administered every 3 weeks for six cycles with antibiotic prophylaxis.

**FEC100 in the PACS 01 trial:** fluorouracil (500 mg/m²), epirubicin (100 mg/m²), and cyclophosphamide (500 mg/m²), all given intravenously every 3 weeks for six cycles.

**FEC100-Docetaxel in the PACS 01 trial:** three cycles of FEC (same as above) followed by docetaxel (100 mg/m²) every 3 weeks for three cycles. FEC-Docetaxel in the UK TACT trial: 5-fluorouracil (600 mg/m²), epirubicin (60 mg/m²), and cyclophosphamide (600 mg/m²) every 3 weeks for four cycles followed by docetaxel (100 mg/m²) every 3 weeks for four cycles.

**FEC in the TACT trial:** same as above for eight cycles. Epirubicin and CMF in the TACT trial: epirubicin (100 mg/m²) every 3 weeks for four cycles, and cyclophosphamide (600 mg/m²), methotrexate (40 mg/m²) and 5-fluorouracil (600 mg/m²) on days 1 and 8 every 4 weeks for four cycles.

**Classical CMF:** cyclophosphamide (100 mg/m² given orally every day for 14 days), methotrexate (40 mg/m²), and fluorouracil (600 mg/m²) given intravenously on days 1 and 8 of the cycle.

**CAF-high dose in the CALGB 8541 trial:** cyclophosphamide (600 mg/m²), doxorubicin (60 mg/m²) and fluorouracil (500 mg/m²), both given intravenously on days 1 every 4 weeks for four cycles. The same dose of 5-fluorouracil was repeated on day 8 of each cycle regardless of hematologic values.

**CAF-moderate dose in the CALGB 8541 trial:** cyclophosphamide (400 mg/m²), doxorubicin (40 mg/m²) and fluorouracil (400 mg/m²), both given intravenously on days 1 every 4 weeks for six cycles. 5-Fluorouracil was repeated on day 8 of each cycle.

**CAF-low dose in the CALGB 8541 trial:** cyclophosphamide (300 mg/m²), doxorubicin (30 mg/m²) and fluorouracil (300 mg/m²), both given intravenously on days 1 every 4 weeks for four cycles. 5-Fluorouracil was repeated on day 8 of each cycle.

**CAF in the Breast Intergroup Trial 001:** cyclophosphamide (100 mg/m²), given orally every day for 14 days; epirubicin (60 mg/m²) and fluorouracil (500 mg/m²), both given intravenously on days 1 and 8 every 4 weeks for six cycles (with routine antibiotic prophylaxis).

**FEC in the GEICAM 9906 trial:** fluorouracil (600 mg/m²), epirubicin (90 mg/m²), and cyclophosphamide (600 mg/m²), all given intravenously every 3 weeks for six cycles.

**FEC-Paclitaxel in the GEICAM 9906 trial:** four cycles of FEC (same as above) followed by paclitaxel 100 mg/m² every week for 8 weeks.